5AM Venture Management’s Celldex Therapeutics CLDX Stock Holding History

5AM Venture Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.5M	Hold	497,270	–	–	6.43%	9
2026 Q1	$15.8M	Hold	497,270	–	–	4.38%	9
2025 Q4	$13.5M	Hold	497,270	–	–	4.25%	10
2025 Q3	$12.9M	Hold	497,270	–	–	4.71%	11
2025 Q2	$10.1M	Hold	497,270	–	–	3.89%	11
2025 Q1	$9.03M	Hold	497,270	–	–	3.41%	12
2024 Q4	$12.6M	Hold	497,270	–	–	3%	16
2024 Q3	$16.9M	Hold	497,270	–	–	3.49%	11
2024 Q2	$18.4M	Hold	497,270	–	–	4.12%	5
2024 Q1	$20.9M	Hold	497,270	–	–	4.67%	5
2023 Q4	$19.7M	Buy	497,270 +187,000	+60%	+$5.5M	5.23%	4
2023 Q3	$8.54M	Hold	310,270	–	–	2.46%	12
2023 Q2	$10.5M	Buy	+310,270	New	+$10.5M	2.62%	10

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

5AM Venture Management's CLDX Position: Q2 2026 in Review

5AM Venture Management held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 497,270 shares worth $18.5M. The position accounts for 6.43% of the portfolio, ranked #9.

5AM Venture Management first reported a position in CLDX in Q2 2023 and has held it in 13 quarters since. The position peaked at $20.9M in Q1 2024. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

5AM Venture Management held 497,270 shares of Celldex Therapeutics worth $18.5M as of Q2 2026.
5AM Venture Management left its Celldex Therapeutics share count unchanged in Q2 2026.
Celldex Therapeutics made up 6.43% of 5AM Venture Management's portfolio in Q2 2026, its #9 holding.
5AM Venture Management first reported a position in Celldex Therapeutics in Q2 2023 and has held it in 13 quarters since.
5AM Venture Management's Celldex Therapeutics position peaked at $20.9M in Q1 2024.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on 5AM Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.